The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease): An Update
Abstract
Membranoproliferative glomerulonephritis type II (MPGN II) is a rare disease characterized by the deposition of abnormal electron-dense material within the glomerular basement membrane of the kidney and often within Bruch's membrane in the eye. The diagnosis is made in most patients between the ages of 5 and 15 yr, and within 10 yr, approximately half progress to end-stage renal disease, occasionally with the late comorbidity of visual impairment. The pathophysiologic basis of MPGN II is associated with the uncontrolled systemic activation of the alternative pathway (AP) of the complement cascade. In most patients, loss of complement regulation is caused by C3 nephritic factor, an autoantibody directed against the C3 convertase of the AP, but in some patients, mutations in the factor H gene have been identified. For the latter patients, plasma replacement therapy prevents renal failure, but for the majority of patients, there is no proven effective treatment. The disease recurs in virtually all renal allografts, and a high percentage of these ultimately fail. The development of molecular diagnostic tools and new therapies directed at controlling the AP of the complement cascade either locally in the kidney or at the systemic level may lead to effective treatments for MPGN II.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Towards a network theory of the immune system.
Jerne, N. K. (1974) · PubMed · Cited by 3,362
(2006) · Elsevier eBooks · doi:10.1016/b978-0-12-595961-2.x5000-8 · Cited by 962
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910 · cited 1×
“Angiotensin-converting enzyme inhibitors and angiotensin II type-1 receptor blockers decrease proteinuria in many glomerular diseases and slow progression to renal failure (93,94).”
BackgroundThe human complement factor H: functional roles, genetic variations and disease associations
RODRIGUEZDECORDOBA, S., ESPARZAGORDILLO, J., GOICOECHEADEJORGE, E., LOPEZTRASCASA, M., & SANCHEZCORRAL, P. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.02.005 · Cited by 574
Control of the amplification convertase of complement by the plasma protein beta1H.
Weiler, J. M., Daha, M. R., Austen, K. F., & Fearon, D. T. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.9.3268 · Cited by 570
Orth, S. R., & Ritz, E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804233381707 · Cited by 533
Pickering, M. C., Cook, H. T., Warren, J., Bygrave, A. E., Moss, J., Walport, M. J., & Botto, M. (2002) · Nature Genetics · doi:10.1038/ng912 · Cited by 518
Self-citationBasta, M., & Dalakas, M. C. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117520 · Cited by 396
Pendergraft, W. F., Preston, G. A., Shah, R. R., Tropsha, A., Carter, C. W., Jennette, J. C., & Falk, R. J. (2004) · Nature Medicine · doi:10.1038/nm968 · Cited by 379
Self-citation
Cited by
Complement C3 variant and the risk of age-related macular degeneration
Yates, J. R. W., Sepp, T., Matharu, B. K., Khan, J. C., Thurlby, D. A., Shahid, H., Clayton, D. G., Hayward, C., Morgan, J., Wright, A. F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072618 · Cited by 829
C3 glomerulopathy: consensus report
Pickering, M. C., D'Agati, V. D., Nester, C. M., Smith, R. J., Haas, M., Appel, G. B., Alpers, C. E., Bajema, I. M., Bedrosian, C., Braun, M., et al. (2013) · Kidney International · doi:10.1038/ki.2013.377 · Cited by 653
Self-citationAge‐related macular degeneration—emerging pathogenetic and therapeutic concepts
Gehrs, K. M., Anderson, D. H., Johnson, L. V., & Hageman, G. S. (2006) · Annals of Medicine · doi:10.1080/07853890600946724 · Cited by 631
Self-citationServais, A., Noël, L.-H., Roumenina, L. T., Le Quintrec, M., Ngo, S., Dragon-Durey, M.-A., Macher, M.-A., Zuber, J., Karras, A., Provot, F., et al. (2012) · Kidney International · doi:10.1038/ki.2012.63 · Cited by 575
Membranoproliferative Glomerulonephritis — A New Look at an Old Entity
Sethi, S., & Fervenza, F. C. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1108178 · Cited by 565
Self-citationThe Central Role of the Alternative Complement Pathway in Human Disease
Thurman, J. M., & Holers, V. M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1305 · Cited by 432
Eculizumab for Dense Deposit Disease and C3 Glomerulonephritis
Bomback, A. S., Smith, R. J., Barile, G. R., Zhang, Y., Heher, E. C., Herlitz, L., Stokes, M. B., Markowitz, G. S., D’Agati, V. D., Canetta, P. A., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12901211 · Cited by 366
Self-citationC3 glomerulopathy: a new classification
Fakhouri, F., Frémeaux-Bacchi, V., Noël, L.-H., Cook, H. T., & Pickering, M. C. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.85 · Cited by 363
Self-citationAge‐related Macular Degeneration (AMD)
(2008) · Encyclopedia of Molecular Pharmacology · doi:10.1007/978-3-540-38918-7_5059 · Cited by 314
Servais, A., Frémeaux-Bacchi, V., Lequintrec, M., Salomon, R., Blouin, J., Knebelmann, B., Grünfeld, J.-P., Lesavre, P., Noël, L.-H., & Fakhouri, F. (2007) · Journal of Medical Genetics · doi:10.1136/jmg.2006.045328 · Cited by 291
De Córdoba, S. R., & De Jorge, E. G. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03552.x · Cited by 287
Heinen, S., Hartmann, A., Lauer, N., Wiehl, U., Dahse, H.-M., Schirmer, S., Gropp, K., Enghardt, T., Wallich, R., Hälbich, S., et al. (2009) · Blood · doi:10.1182/blood-2009-02-205641 · Cited by 272
Self-citationC3 Glomerulopathy: Clinicopathologic Features and Predictors of Outcome
Medjeral-Thomas, N. R., O’Shaughnessy, M. M., O’Regan, J. A., Traynor, C., Flanagan, M., Wong, L., Teoh, C. W., Awan, A., Waldron, M., Cairns, T., et al. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04700513 · Cited by 256
Self-citationFactor H family proteins and human diseases
Józsi, M., & Zipfel, P. F. (2008) · Trends in Immunology · doi:10.1016/j.it.2008.04.008 · Cited by 254
Self-citationSelf‐nonself discrimination by the complement system
Meri, S. (2016) · FEBS Letters · doi:10.1002/1873-3468.12284 · Cited by 87
Self-citationBao, L., Wang, Y., Chang, A., Minto, A. W., Zhou, J., Kang, H., Haas, M., & Quigg, R. J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006101176 · Cited by 51
Montes, T., Goicoechea de Jorge, E., Ramos, R., Gomà, M., Pujol, O., Sánchez-Corral, P., & Rodríguez de Córdoba, S. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2008.01.027 · Cited by 47
Metadata
- Authors
- Appel, G. B., Cook, H. T., Hageman, G., Jennette, J. C., Kashgarian, M., Kirschfink, M., Lambris, J. D., Lanning, L., Lutz, H. U., Meri, S., Rose, N. R., Salant, D. J., Sethi, S., Smith, R. J. H., Smoyer, W., Tully, H. F., Tully, S. P., Walker, P., Welsh, M., Wu[Combining Diaeresis]rzner, R., & Zipfel, P. F.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2005-05
- Volume
- 16
- Issue
- 5
- Pages
- 1392-1403
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2162002618
- Cited by
- 380
- References
- 50
- FWCI
- 8.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.